These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

712 related articles for article (PubMed ID: 8784011)

  • 1. Molecular markers help characterize neuroendocrine lung tumors.
    Rusch VW; Klimstra DS; Venkatraman ES
    Ann Thorac Surg; 1996 Sep; 62(3):798-809; discussion 809-10. PubMed ID: 8784011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.
    Przygodzki RM; Finkelstein SD; Langer JC; Swalsky PA; Fishback N; Bakker A; Guinee DG; Koss M; Travis WD
    Am J Pathol; 1996 May; 148(5):1531-41. PubMed ID: 8623922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival.
    Skov BG; Holm B; Erreboe A; Skov T; Mellemgaard A
    J Thorac Oncol; 2010 Apr; 5(4):453-9. PubMed ID: 20104194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pulmonary neuroendocrine tumors in the new WHO 2015 classification: Start of breaking new grounds?].
    Schnabel PA; Junker K
    Pathologe; 2015 May; 36(3):283-92. PubMed ID: 25956813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid.
    Travis WD; Rush W; Flieder DB; Falk R; Fleming MV; Gal AA; Koss MN
    Am J Surg Pathol; 1998 Aug; 22(8):934-44. PubMed ID: 9706973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular markers for reinforcement of histological subclassification of neuroendocrine lung tumors.
    Kobayashi Y; Tokuchi Y; Hashimoto T; Hayashi M; Nishimura H; Ishikawa Y; Nakagawa K; Sato Y; Takahashi A; Tsuchiya E
    Cancer Sci; 2004 Apr; 95(4):334-41. PubMed ID: 15072592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumour suppressor gene products, proliferation, and differentiation markers in lung neuroendocrine neoplasms.
    Barbareschi M; Girlando S; Mauri FA; Arrigoni G; Laurino L; Dalla Palma P; Doglioni C
    J Pathol; 1992 Apr; 166(4):343-50. PubMed ID: 1355531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. hASH1 is a specific immunohistochemical marker for lung neuroendocrine tumors.
    Ye B; Cappel J; Findeis-Hosey J; McMahon L; Yang Q; Xiao GQ; Xu H; Li F
    Hum Pathol; 2016 Feb; 48():142-7. PubMed ID: 26596584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Automated quantification of Ki-67 proliferative index of excised neuroendocrine tumors of the lung.
    Liu SZ; Staats PN; Goicochea L; Alexiev BA; Shah N; Dixon R; Burke AP
    Diagn Pathol; 2014 Oct; 9():174. PubMed ID: 25318848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bcl-2, p53, CD44, and CD44v6 isoform expression in neuroendocrine tumors of the lung.
    Coppola D; Clarke M; Landreneau R; Weyant RJ; Cooper D; Yousem SA
    Mod Pathol; 1996 May; 9(5):484-90. PubMed ID: 8733762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential retinoblastoma and p16(INK4A) protein expression in neuroendocrine tumors of the lung.
    Dosaka-Akita H; Cagle PT; Hiroumi H; Fujita M; Yamashita M; Sharma A; Kawakami Y; Benedict WF
    Cancer; 2000 Feb; 88(3):550-6. PubMed ID: 10649246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apoptosis-related factors p53, Bcl2, and Bax in neuroendocrine lung tumors.
    Brambilla E; Negoescu A; Gazzeri S; Lantuejoul S; Moro D; Brambilla C; Coll JL
    Am J Pathol; 1996 Dec; 149(6):1941-52. PubMed ID: 8952529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in neuroendocrine lung tumors.
    Travis WD
    Ann Oncol; 2010 Oct; 21 Suppl 7():vii65-71. PubMed ID: 20943645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroendocrine tumors of the lung: A five-year retrospective experience of Egyptian NCI (2010-2014).
    Saber M; Ismail Y; Alieldin N; Loay I; El Zawahry M
    J Egypt Natl Canc Inst; 2018 Dec; 30(4):151-158. PubMed ID: 30470605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulmonary neuroendocrine tumors: study of 90 cases focusing on clinicopathological characteristics, immunophenotype, preoperative biopsy, and frozen section diagnoses.
    Yeh YC; Chou TY
    J Surg Oncol; 2014 Mar; 109(3):280-6. PubMed ID: 24301337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Large cell neuroendocrine carcinoma of the lung: a histologic and immunohistochemical study of 22 cases.
    Jiang SX; Kameya T; Shoji M; Dobashi Y; Shinada J; Yoshimura H
    Am J Surg Pathol; 1998 May; 22(5):526-37. PubMed ID: 9591721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative evaluation of three proliferation markers, Ki-67, TOP2A, and RacGAP1, in bronchopulmonary neuroendocrine neoplasms: Issues and prospects.
    Neubauer E; Wirtz RM; Kaemmerer D; Athelogou M; Schmidt L; Sänger J; Lupp A
    Oncotarget; 2016 Jul; 7(27):41959-41973. PubMed ID: 27259241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential retinoblastoma protein expression in neuroendocrine tumors of the lung. Potential diagnostic implications.
    Cagle PT; el-Naggar AK; Xu HJ; Hu SX; Benedict WF
    Am J Pathol; 1997 Feb; 150(2):393-400. PubMed ID: 9033254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pulmonary neuroendocrine tumors and preneoplasic lesions].
    Rouquette Lassalle I
    Ann Pathol; 2016 Jan; 36(1):34-43. PubMed ID: 26776366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of thyroid transcription factor-1 in the spectrum of neuroendocrine cell lung proliferations with special interest in carcinoids.
    Sturm N; Rossi G; Lantuejoul S; Papotti M; Frachon S; Claraz C; Brichon PY; Brambilla C; Brambilla E
    Hum Pathol; 2002 Feb; 33(2):175-82. PubMed ID: 11957142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.